News
PureCircle receives ‘no objection’ for SG95 stevia product
The US Food and Drug Administration (FDA) has issued a ‘no objection’ letter for the use of PureCircle’s SG95 product as a food and beverage ingredient in the US.
This will enable PureCircle to offer a wider and more flexible array of stevia solutions to manufacturers in the US market.
Along with seven previously approved steviol glycosides, SG95 includes two new steviol glycosides, Rebaudioside D and Rebaudioside F, both of which are receiving Gras ‘no objection’ for the first time.
With Gras affirmation, PureCircle is prepared for immediate commercialisation of SG95. Magomet Malsagov, CEO and MD of PureCircle, said: “The launch of SG95 is a very exciting development for PureCircle in the US, with considerable future potential in global markets. Expanded use of sweet glycosides from the stevia plant provides formulation and economic benefits to our customers.
“Our Reb A 97 continues to play a major role in our portfolio, particularly as our investments yield continued efficiencies that will be shared with our customers. Now, SG95 will provide an additional compelling product today in many applications. We’re proud to continue to be at the forefront of innovation to help mainstream a better sweet choice for consumers. ”
Source: PureCircle
- If you enjoyed this article, you may also like this: EFSA evaluates safety of stevia
- You may also like to see our stevia gallery.
See also
Latest news
| |